1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2019.
http://www.goldcopd.org/
. Accessed 08 Aug 2019.
2. AstraZeneca Pharmaceuticals. Bevespi Aerosphere™ (glycopyrrolate and formoterol fumarate) inhalation aerosol: US prescribing information. 2016.
http://www.azpicentral.com/
. Accessed 08 Aug 2019.
3. European Medicines Agency. Summary of product characteristics: Bevespi Aerosphere 7.2 micrograms/5 micrograms pressurised inhalation, suspension. 2019.
http://www.ema.europa.eu/
. Accessed 08 Aug 2019.
4. AstraZeneca Pharmaceuticals. Bevespi Aerosphere (glycopyrronium/formoterol fumarate): Japanese prescribing information. 2019.
http://www.pmda.go.jp/
. Accessed 08 Aug 2019.
5. Martinez FJ, Rabe KF, Ferguson GT, et al. Efficacy and safety of glycopyrrolate/formoterol metered dose inhaler formulated using co-suspension delivery technology in patients with COPD. Chest. 2017;151(2):340–57.